Edmonton keeping eye out for ‘relentless killer' in tree canopy
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
12 hours ago
- Globe and Mail
B-cell Non-hodgkin Lymphoma Clinical Trials, Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis
"B-cell Non-hodgkin Lymphoma Pipeline Insights" DelveInsight's, 'B-Cell Non-Hodgkin Lymphoma - Pipeline Insight, 2025' report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in B-Cell Non-Hodgkin Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. According to DelveInsight, over 75 major companies are actively engaged in the development of more than 80 treatment therapies for B-cell non-Hodgkin lymphoma. B-cell Non-hodgkin Lymphoma Overview: B-cell non-Hodgkin lymphoma (NHL) is a type of cancer that arises from abnormal B lymphocytes—white blood cells essential to the immune system. It accounts for over 85% of all NHL cases, making it the most common subtype. B-cell NHL includes several subtypes, classified based on cell morphology, surface proteins, and genetic traits. Key subtypes include diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and Burkitt lymphoma. The disease typically starts in the lymph nodes or lymphoid tissues and can spread to other organs, such as the gastrointestinal tract. Common symptoms include painless swollen lymph nodes, fever, night sweats, fatigue, weight loss, itchy skin, and pain in the chest, abdomen, or bones. When fever, night sweats, and weight loss occur together, they are known as B symptoms and are important for staging and prognosis. Diagnosing B-cell NHL—especially types with small- to medium-sized cells—can be difficult due to their resemblance to reactive lymphadenopathy and other lymphomas. Accurate diagnosis relies on a combination of techniques, including immunohistochemistry and flow cytometry, which must be interpreted in the context of the patient's clinical presentation and cellular morphology. Proper recognition of cytologic features is key to choosing the right diagnostic tests. Subtypes such as marginal zone lymphoma, follicular lymphoma, mantle cell lymphoma, CLL/SLL, and lymphoplasmacytic lymphoma are often misdiagnosed based on cytology alone. Therefore, a lymph node biopsy is usually necessary for definitive diagnosis and proper classification. "B-cell Non-hodgkin Lymphoma Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the B-cell Non-hodgkin Lymphoma Therapeutics Market. Key Takeaways from the B-cell Non-hodgkin Lymphoma Pipeline Report DelveInsight's B-cell Non-hodgkin Lymphoma pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for B-cell Non-hodgkin Lymphoma treatment. In May 2023, Bristol Myers Squibb announced positive topline results from two studies: TRANSCEND FL, a global, multicenter Phase 2 study evaluating Breyanzi (lisocabtagene maraleucel) in patients with relapsed or refractory follicular lymphoma (FL), and TRANSCEND NHL 001, a pivotal Phase 1 study assessing Breyanzi in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL), including mantle cell lymphoma (MCL). Both studies met the primary endpoint of overall response rate, with Breyanzi showing statistically significant and clinically meaningful responses in relapsed or refractory FL and MCL. In May 2023, Janssen Biotech, a subsidiary of Johnson & Johnson, announced a global collaboration and licensing agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture, and commercialize next-generation CAR T-cell therapies for treating B-cell malignancies. In May 2023, Genmab A/S revealed that the FDA approved EPKINLY™ (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from indolent lymphoma, after two or more lines of systemic therapy. In January 2023, Fate Therapeutics, Inc. announced it had declined a proposal from Janssen Biotech to continue their collaboration and option agreement under revised terms, leading to the termination of the agreement and the winding down of all collaboration activities in the first quarter of 2023. Key B-cell Non-hodgkin Lymphoma companies such as Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy, Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics, and others are evaluating new drugs for B-cell Non-hodgkin Lymphoma to improve the treatment landscape. Promising B-cell Non-hodgkin Lymphoma pipeline therapies in various stages of development include Valemetostat, MB-106, CB-010, LP-284, and others. B-cell Non-hodgkin Lymphoma Pipeline Analysis The report provides insights into: The report provides detailed insights into the key companies that are developing therapies in the B-cell Non-hodgkin Lymphoma Market. The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for B-cell Non-hodgkin Lymphoma treatment. It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the B-cell Non-hodgkin Lymphoma market. Download our free sample page report on B-cell Non-hodgkin Lymphoma pipeline insights B-cell Non-hodgkin Lymphoma Emerging Drugs Valemetostat: Daiichi Sankyo MB-106: Mustang Bio CB-010: Caribou Biosciences LP-284: Lantern Pharma B-cell Non-hodgkin Lymphoma Companies Over 75 key companies are working on developing therapies for B-cell non-Hodgkin lymphoma. Among them, Daiichi Sankyo has drug candidates for B-cell non-Hodgkin lymphoma in the advanced Phase II stage. DelveInsight's report covers around 22+ products under different phases of clinical development like Late stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) along with the details of Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates B-cell Non-hodgkin Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intravenous Subcutaneous Oral Intramuscular B-cell Non-hodgkin Lymphoma Products have been categorized under various Molecule types such as Monoclonal antibody Small molecule Peptide Download Sample Pages to Get an in-depth Assessment of the Emerging B-cell Non-hodgkin Lymphoma Therapies and Key Companies: B-cell Non-hodgkin Lymphoma Clinical Trials and advancements B-cell Non-hodgkin Lymphoma Pipeline Therapeutic Assessment • B-cell Non-hodgkin Lymphoma Assessment by Product Type • B-cell Non-hodgkin Lymphoma By Stage • B-cell Non-hodgkin Lymphoma Assessment by Route of Administration • B-cell Non-hodgkin Lymphoma Assessment by Molecule Type Download B-cell Non-hodgkin Lymphoma Sample report to know in detail about the B-cell Non-hodgkin Lymphoma treatment market @ B-cell Non-hodgkin Lymphoma Therapeutic Assessment Table of Content 1. Report Introduction 2. Executive Summary 3. B-cell Non-hodgkin Lymphoma Current Treatment Patterns 4. B-cell Non-hodgkin Lymphoma - DelveInsight's Analytical Perspective 5. Therapeutic Assessment 6. B-cell Non-hodgkin Lymphoma Late-Stage Products (Phase-III) 7. B-cell Non-hodgkin Lymphoma Mid-Stage Products (Phase-II) 8. Early Stage Products (Phase-I) 9. Pre-clinical Products and Discovery Stage Products 10. Inactive Products 11. Dormant Products 12. B-cell Non-hodgkin Lymphoma Discontinued Products 13. B-cell Non-hodgkin Lymphoma Product Profiles 14. B-cell Non-hodgkin Lymphoma Key Companies 15. B-cell Non-hodgkin Lymphoma Key Products 16. Dormant and Discontinued Products 17. B-cell Non-hodgkin Lymphoma Unmet Needs 18. B-cell Non-hodgkin Lymphoma Future Perspectives 19. B-cell Non-hodgkin Lymphoma Analyst Review 20. Appendix 21. Report Methodology Request the Sample PDF to Get Detailed Insights About the B-cell Non-hodgkin Lymphoma Pipeline Reports Offerings Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Kritika Rehani Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
National Post
15 hours ago
- National Post
How to see the letters X and V on the moon tonight
The full moon is a glorious sight, and the sliver of a brand-new moon a wispy delight, but tonight's first-quarter moon has its own unique treat — for a few hours, you can make out the letters X and V on the lunar surface. Here's how. Article content Article content As the photo shows, the lunar X appears about a third of the way from the bottom of the moon, while the Lunar V is a little above the centre. Both features straddle the line between the light and dark sides of the moon, known as the terminator, with the X appearing a little into the dark side, and the V closer to the light side. Article content Why do the letters appear? Article content Article content They're not really there on the surface, and you can't see them at any other time. What you're looking at is called the 'clair-obscur' effect, in which the play of light and shadow on the surface creates the appearance of shapes; in this case, giant letters, formed by the partially lit edges of craters. Article content According to British astronomer Mary McIntyre, the effect kicks off tonight at about 7:30 p.m. ET, and should last about four hours. That means by the time the sun has set and the moon is at its brightest, you should be able to get a good look, clouds permitting. Article content What's the best way to see them? Article content Naked eye is a little tricky, since they are quite small. But decent binoculars (or better yet a small telescope) should bring them into focus. Article content Humans have been looking at the moon since we were human, and through telescopes since they were invented, so it's not surprising that other transient shapes have been noticed and given evocative names, including the jewelled handle, Cassini's moon maiden, Plato's hook and the eyes of Clavius, not to mention the so-called 'man in the moon' that many people see in the full moon. Article content McIntyre has a chart of when to look for them, while BBC's Sky at Night Magazine has a nice picture that shows their locations. The best part about all this is that if you miss them, they'll come back again every 28 days, forever. Article content
CTV News
15 hours ago
- CTV News
Why is there no life on Mars? Rover finds a clue
This image made available by NASA shows the planet Mars. (NASA via AP, File) Why is Mars barren and uninhabitable, while life has always thrived here on our relatively similar planet Earth? A discovery made by a NASA rover has offered a clue for this mystery, new research said Wednesday, suggesting that while rivers once sporadically flowed on Mars, it was doomed to mostly be a desert planet. Mars is thought to currently have all the necessary ingredients for life except for perhaps the most important one: liquid water. However the red surface is carved out by ancient rivers and lakes, showing that water once flowed on our nearest neighbour. There are currently several rovers searching Mars for signs of life that could have existed back in those more habitable times, millions of years ago. Earlier this year, NASA's Curiosity rover discovered a missing piece in this puzzle: rocks that are rich in carbonate minerals. These 'carbonates' -- such as limestone on Earth -- act as a sponge for carbon dioxide, pulling it in from the atmosphere and trapping it in rock. A new study, published in the journal Nature, modelled exactly how the existence of these rocks could change our understanding of Mars's past. Brief 'oases' Lead study author Edwin Kite, a planetary scientist at the University of Chicago and a member of the Curiosity team, told AFP it appeared there were 'blips of habitability in some times and places' on Mars. But these 'oases' were the exception rather than the rule. On Earth, carbon dioxide in the atmosphere warms the planet. Over long timescales, the carbon becomes trapped in rocks such as carbonates. Then volcanic eruptions spew the gas back into the atmosphere, creating a well-balanced climate cycle supportive of consistently running water. However Mars has a 'feeble' rate of volcanic outgassing compared to Earth, Kite said. This throws off the balance, leaving Mars much colder and less hospitable. According to the modelling research, the brief periods of liquid water on Mars were followed by 100 million years of barren desert -- a long time for anything to survive. It is still possible that there are pockets of liquid water deep underground on Mars we have not yet found, Kite said. NASA's Perseverance Rover, which landed on an ancient Martian delta in 2021, has also found signs of carbonates at the edge of dried-up lake, he added. Next, the scientists hope to discover more evidence of carbonates. Kite said the best proof would be returning rock samples from the Martian surface back to Earth -- both the United States and China are racing to do this in the next decade. Are we alone? Ultimately, scientists are searching for an answer to one of the great questions: how common are planets like Earth that can harbour life? Astronomers have discovered nearly 6,000 planets beyond our Solar System since the early 1990s. But only for Mars and Earth can scientists study rocks which allow them to understand the planet's past, Kite said. If we do determine that Mars never hosted even tiny micro-organisms during its watery times, that would indicate it is difficult to kick-start life across the universe. But if we discover proof of ancient life, that would 'basically be telling us the origin of life is easy on a planetary scale,' Kite said.
